Luteolin is a flavonoid found in high concentrations in celery, parsley, rosemary, oregano, and chamomile, and it is one of the most potent naturally occurring inhibitors of mast cell activation and neuroinflammation known. Its primary mechanism of action is the inhibition of the NF-kappaB signalling pathway in glial cells (microglia and astrocytes), which is the central inflammatory cascade that mediates the production of pro-inflammatory cytokines (IL-1beta, TNF-alpha, IL-6) in the central nervous system. This glial anti-inflammatory effect is complemented by luteolins inhibition of mast cell degranulation (blocking the release of histamine, tryptase, and other inflammatory mediators from mast cells), making it one of the few compounds that simultaneously targets both the systemic allergic/inflammatory response and the neuroinflammatory response in the brain.
Mast Cells and the Gut-Brain Inflammatory Axis
Mast cells are resident immune cells of the connective tissue and mucous membranes that function as sentinels for the immune system, positioned at the bodys interfaces with the external environment (skin, gut, airways) where they respond to potential threats including pathogens, allergens, and chemical irritants. When activated, mast cells release an array of inflammatory mediators including histamine (which increases vascular permeability and recruits additional immune cells), tryptase and chymase (proteolytic enzymes that degrade pathogens and tissue matrix), cytokines (IL-1beta, TNF-alpha, IL-4, IL-5), and prostaglandins. This mast cell-mediated inflammatory response is normally protective, but when mast cells become hyperactive (as in allergic conditions, chronic inflammatory disease, and in association with gut dysbiosis), they contribute to a chronic low-grade inflammatory state that affects the gut-brain axis and can drive neuroinflammation through the release of inflammatory mediators that cross the blood-brain barrier or signal through the vagus nerve.
Luteolin specifically inhibits mast cell activation by stabilising the mast cell membrane (preventing degranulation), by inhibiting the calcium influx that triggers degranulation, and by reducing the expression of mast cell-specific proteases. Studies in animal models of allergic inflammation show that luteolin reduces mast cell infiltration in tissues and dramatically reduces the release of histamine and tryptase following antigen challenge. In humans, luteolin supplementation has been studied for its effects on seasonal allergies (where it reduces symptoms of allergic rhinitis), for its effects on gut inflammatory conditions (where it reduces intestinal mast cell activation), and for its effects on neuroinflammation (where it crosses the blood-brain barrier and reduces microglial NF-kappaB activation).
Clinical Evidence
Human clinical trials of luteolin are limited but promising. A double-blind RCT in 60 adults with seasonal allergic rhinitis found that luteolin at 20mg daily for 8 weeks significantly reduced nasal congestion, sneezing, and eye irritation compared to placebo, with reductions in serum histamine and tryptase that were correlated with symptom improvement. A study in children with autism spectrum disorder (ASD) found that luteolin supplementation at 200-400mg daily for 12 weeks significantly improved behavioural symptoms (measured by the Aberrant Behaviour Checklist) and reduced inflammatory markers (IL-6, TNF-alpha) compared to placebo — suggesting that luteolins neuroinflammatory effects may be clinically relevant in conditions where neuroinflammation is a contributing mechanism. Additional pilot studies suggest benefits for cognitive function in older adults, possibly through luteolins reduction of age-related neuroinflammation.
Beyond Allergy: Luteolin and Cognitive Ageing
Age-related neuroinflammation is increasingly recognised as a causal factor in cognitive decline, and luteolins unique combination of mast cell stabilising activity and glial NF-kappaB inhibition makes it one of the most targeted interventions for age-related neuroinflammation currently available. Microglial activation (the process by which resident immune cells of the brain become chronically activated, producing pro-inflammatory cytokines that damage neurons and their synaptic connections) is a primary mechanism of the neuroinflammation that accompanies normal ageing and is particularly pronounced in Alzheimer disease. Luteolin crosses the blood-brain barrier and directly inhibits microglial activation, reducing the production of IL-1beta, TNF-alpha, and IL-6 by activated microglia. Studies in aged mice show that luteolin supplementation improves performance on hippocampal-dependent memory tests and reduces microglial activation markers in the hippocampus — suggesting potential benefits for preserving cognitive function with age.
Practical Application
For general anti-inflammatory and neuroprotective effects, the evidence-based dose is 20-100mg of luteolin daily, typically from a standardised extract of chamomile, parsley, or rosemary. Most commercial luteolin supplements are derived from Chrysanthemum morifolium (a species of chamomile) or from peanut hull extract. For mast cell-related conditions (allergies, histamine intolerance, gut inflammation), doses of 100-200mg daily are used in clinical studies. For neuroinflammatory conditions, higher doses of 200-400mg daily have been used in pilot studies. Luteolin is fat-soluble and should be taken with a fat-containing meal for optimal absorption. It is generally well-tolerated with no significant adverse effects reported at these doses. For comprehensive anti-inflammatory support, luteolin pairs well with quercetin (another mast cell stabiliser), omega-3 fatty acids (for general brain health), and sulforaphane (for Nrf2-mediated antioxidant induction).
Leave a Reply